RHHBY - Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges | Benzinga
Tuesday, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) said the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension, met the primary endpoint.
The data showed that zilebesiran resulted in clinically and statistically significant additive, placebo-adjusted reductions in 24-hour mean systolic blood pressure (SBP) at Month 3 in each of three independent patient cohorts receiving the standardized background therapies of either a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan).
Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard-of-care antihypertensives.
Zilebesiran is being co-developed and co-commercialized by Alnylam and Roche Holdings AG (OTC:RHHBY).
Alnylam and Roche also initiated a ...